Lexington, MA – September 07th, 2022 – CILcare, a leading CRO specializing in hearing disorders, announced today that the company and its partner, CBSET Inc., a not-for-profit translational research institute, have been nominated at the Hearing Technology Innovator Awards in the Prevention & Therapeutics category. This nomination highlights the five years long partnership between CILcare and CBSET, and their efforts to accelerate the development of innovative solutions to hearing disorders together since 2017.
The Hearing Technology Innovator Awards are a yearly initiative organized by Hearing Health & Technology Matters, which honors technological innovation and achievement in the hearing industry. Prestigious actors from the field like Frequency Therapeutics, Cochlear, and Advanced Bionics were among last year’s winners. Not only these awards highlight and celebrate innovation within the hearing industry, but they are also an opportunity to raise funds for the Hearing Loss Association of America and the Hearing Health Foundation.
Vote for CILcare-CBSET here. Voting is open until Thursday, September 15.
CILcare, with headquarters in Montpellier, France, and offices in Paris, Boston and Copenhagen, is a CRO specializing in otology. CILcare has state-of-the-art laboratories, research experts in otology and neuroscience, as well as a global network of partners, enabling CILcare to offer fully customizable and comprehensive R&D programs including pharmacokinetics, preclinical efficacy, and GLP ototoxicity studies. Learn more about CILcare’s expert R&D services dedicated to ear disorders.
CBSET is a state-of-the-art biomedical research institute located in Lexington, Mass. As a not-for-profit entity, our mission is to advance biomedical research through innovative, high-quality preclinical services to achieve the scientific, regulatory and commercial goals of our sponsors. Our 40,000-foot, GLP-compliant, OLAW-assured, AAALAC-accredited facility includes vivaria, procedure rooms, catheterization / imaging labs, surgical and necropsy suites, histopathology, SEM, and a range of other technologies. We provide top-tier research with operational expertise by combining in vivo studies, in vitro studies, computational and 3D modeling, and complex histopathology into one integrated paradigm. Since inception, CBSET continues to develop technical and scientific acumen through collaborative projects in the medical device, pharmaceutical and academic communities. Learn more about CBSET’s expert biomedical research services.
See all Member News